Trump's executive order elevates cannabis research while a new hemp ban looms, easing industry uncertainty and opening doors.

A recent review published in JAMA found that the evidence to support the use of cannabis and cannabinoids for most medical ...

High Alert - which issues warnings about dangerous or misrepresented drugs - says it's currently unknown which synthetic cannabinoids are responsible. But it's very likely present throughout Auckland, ...

Northeastern University researchers have made a breakthrough drug discovery, developing the first synthetic endogenous ...

Emerging evidence highlights psilocybin as a potential therapy for treatment-resistant OCD, while cannabinoids show limited ...

A shift toward science-backed products has created new opportunities for research-focused companies emphasizing traceability, low-temperature extraction, and careful sourcing. One such business, True ...

While current data on medical cannabinoids in rheumatology is limited, findings suggest that adverse events (AEs) and drug interactions outweigh the benefits. When evaluating whether cannabinoids used ...

New psychoactive substances, originally developed as potential analgesics but abandoned due to adverse side effects, may still have pharmaceutical value if researchers could nail down the causes of ...

While unclear if, how, or by whom the appropriations bill’s hemp prohibition will be enforced, on Dec. 12, 2025, the ...

Cannabinoids are naturally occurring compounds found in the Cannabis sativa plant. Of over 480 different compounds present in the plant, only around 66 are termed cannabinoids. The most well known ...

The legalization of cannabis has created many opportunities for researchers to study the compounds in the cannabinoid family and discover new uses for them. Demetrix, a synthetic biology company ...